Post-translational Modifications of EZH2 in Cancer

Overview

Journal Cell Biosci

Publisher Biomed Central

Specialty Biology

Date 2020 Dec 14

PMID 33308321

Citations 39

Authors

Zhongwei Li

Minle Li

Diandian Wang

Pingfu Hou

Xintian Chen

Sufang Chu

Dafei Chai

Junnian Zheng

Jin Bai

Affiliations

Soon will be listed here.

Abstract

Enhancer of zeste homolog 2 (EZH2), as a main component of Polycomb Repressive Complex 2, catalyzes histone H3K27me3 to silence its target gene expression. EZH2 upregulation results in cancer development and poor prognosis of cancer patients. Post-translational modifications (PTMs) are important biological events in cancer progression. PTMs regulate protein conformation and diversity functions. Recently, mounting studies have demonstrated that EZH2 stability, histone methyltransferase activity, localization, and binding partners can be regulated by PTMs, including phosphorylation, O-GlcNAcylation, acetylation, methylation and ubiquitination. However, the detailed molecular mechanisms of the EZH2-PTMs and whether other types of PTMs occur in EZH2 remain largely unclear. This review presents an overview of different roles of EZH2 modification and EZH2-PTMs crosstalk during tumorigenesis and cancer metastasis. We also discussed the therapeutic potential of targeting EZH2 modifications for cancer therapy.

Citing Articles

CRISPR detection of cardiac tumor-associated microRNAs.

Fu Y, Zhang P, Chen F, Xie Z, Xiao S, Huang Z Mol Biol Rep. 2025; 52(1):114.

PMID: 39797940 DOI: 10.1007/s11033-024-10205-4.

Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential.

Gilardini Montani M, Benedetti R, Cirone M Molecules. 2025; 29(24.

PMID: 39769907 PMC: 11678268. DOI: 10.3390/molecules29245817.

SUMO E3 ligase MUL1 inhibits lymph node metastasis of bladder cancer by mediating mitochondrial HSPA9 translocation.

Wu J, Huang M, Dong W, Chen Y, Zhou Q, Zhang Q Int J Biol Sci. 2024; 20(10):3986-4006.

PMID: 39113711 PMC: 11302872. DOI: 10.7150/ijbs.98772.

EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.

Guo S, Tang Q, Gao X, Hu L, Hu K, Zhang H Acta Biochim Biophys Sin (Shanghai). 2024; 56(7):1055-1064.

PMID: 38804044 PMC: 11322866. DOI: 10.3724/abbs.2024077.

A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis.

Guo P, Lim R, Rajawasam K, Trinh T, Sun H, Zhang H Elife. 2024; 13.

PMID: 38346162 PMC: 10901513. DOI: 10.7554/eLife.86168.

References

Clague M, Urbe S . Ubiquitin: same molecule, different degradation pathways. Cell. 2010; 143(5):682-5. DOI: 10.1016/j.cell.2010.11.012. View

Johnson S, Hunter T . Kinomics: methods for deciphering the kinome. Nat Methods. 2005; 2(1):17-25. DOI: 10.1038/nmeth731. View

Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

Wang X, Cao W, Zhang J, Yan M, Xu Q, Wu X . A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J. 2017; 36(9):1243-1260. PMC: 5412902. DOI: 10.15252/embj.201694058. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Shen Z, Chen L, Yang X, Zhao Y, Pier E, Zhang X . Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?. Biochim Biophys Acta. 2013; 1833(10):2190-200. DOI: 10.1016/j.bbamcr.2013.05.014. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Ma L, Lin K, Chang G, Chen Y, Yue C, Guo Q . Aberrant Activation of β-Catenin Signaling Drives Glioma Tumorigenesis via USP1-Mediated Stabilization of EZH2. Cancer Res. 2018; 79(1):72-85. PMC: 9646285. DOI: 10.1158/0008-5472.CAN-18-1304. View

Geiss-Friedlander R, Melchior F . Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007; 8(12):947-56. DOI: 10.1038/nrm2293. View

10.

Chen S, Yao X, Li Y, Saifudeen Z, Bachvarov D, El-Dahr S . Histone deacetylase 1 and 2 regulate Wnt and p53 pathways in the ureteric bud epithelium. Development. 2015; 142(6):1180-92. PMC: 4360175. DOI: 10.1242/dev.113506. View

11.

Ryan R, Nitta M, Borger D, Zukerberg L, Ferry J, Lee Harris N . EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One. 2011; 6(12):e28585. PMC: 3237460. DOI: 10.1371/journal.pone.0028585. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Zhao D, Zou S, Liu Y, Zhou X, Mo Y, Wang P . Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 2013; 23(4):464-76. PMC: 3885615. DOI: 10.1016/j.ccr.2013.02.005. View

14.

Xiao Z, Zhang P, Ma L . The role of deubiquitinases in breast cancer. Cancer Metastasis Rev. 2016; 35(4):589-600. PMC: 5215973. DOI: 10.1007/s10555-016-9640-2. View

15.

Ito T, Teo Y, Evans S, Neretti N, Sedivy J . Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways. Cell Rep. 2018; 22(13):3480-3492. PMC: 5915310. DOI: 10.1016/j.celrep.2018.03.002. View

16.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

17.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

18.

Jin B, Zhang P, Zou H, Ye H, Wang Y, Zhang J . Verification of EZH2 as a druggable target in metastatic uveal melanoma. Mol Cancer. 2020; 19(1):52. PMC: 7055080. DOI: 10.1186/s12943-020-01173-x. View

19.

Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q . ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep. 2018; 23(3):823-837. PMC: 5933875. DOI: 10.1016/j.celrep.2018.03.078. View

20.

Ko F, Wu C, Kuo S, Lee F, Teng C . YC-1, a novel activator of platelet guanylate cyclase. Blood. 1994; 84(12):4226-33. View